fluorescent ligands

19 July 2023

Celtarys extends its chemical conjugation technology to the development of new fluorescent ligands for E3 Ubiquitin ligases

Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023

CELTARY & NANOTEMPER-Discovery partnership to enhance performance in GPCR characterization

Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
27 January 2023

The advantages to using fluorescence vs radioactivity in receptors kinetic and binding assays.

WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023

Transform your idea in to molecules

Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
18 November 2022

Discover Our New Fluorescent Ligands For Adrenergic Receptor

Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue two more fluorescent ligands for the α1-Adrenergic receptor, CELT-130 and CELT-133. α1-Adrenergic receptors play a vital role in the regulation of […]
26 July 2022

Celtarys Adenosine Receptor fluorescent ligands as potent tools for the study of cancer specific GPCRs

The ONCOMET group from the Health Research Institute of Santiago led by Dr. Miguel Abal has published an interesting article showing tumor and stromal-specific genetic signatures […]